Identifying States of Collateral Sensitivity during the Evolution of Therapeutic Resistance in Ewing's Sarcoma.
Biological Sciences
Cancer
Cancer Systems Biology
Evolutionary Biology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
24 Jul 2020
24 Jul 2020
Historique:
received:
12
02
2020
revised:
06
05
2020
accepted:
15
06
2020
pubmed:
6
7
2020
medline:
6
7
2020
entrez:
6
7
2020
Statut:
ppublish
Résumé
Advances in the treatment of Ewing's sarcoma (EWS) are desperately needed, particularly in the case of metastatic disease. A deeper understanding of collateral sensitivity, where the evolution of therapeutic resistance to one drug aligns with sensitivity to another drug, may improve our ability to effectively target this disease. For the first time in a solid tumor, we produced a temporal collateral sensitivity map that demonstrates the evolution of collateral sensitivity and resistance in EWS. We found that the evolution of collateral resistance was predictable with some drugs but had significant variation in response to other drugs. Using this map of temporal collateral sensitivity in EWS, we can see that the path toward collateral sensitivity is not always repeatable, nor is there always a clear trajectory toward resistance or sensitivity. Identifying transcriptomic changes that accompany these states of transient collateral sensitivity could improve treatment planning for patients with EWS.
Identifiants
pubmed: 32623338
pii: S2589-0042(20)30480-6
doi: 10.1016/j.isci.2020.101293
pmc: PMC7334607
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101293Subventions
Organisme : NCI NIH HHS
ID : K12 CA076917
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA162069
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA244613
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007250
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests Stephen Lessnick serves as a Scientific Advisor for Salarius Pharmaceuticals.
Références
Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):139-150
pubmed: 28161395
Oncotarget. 2014 Jun 30;5(12):4516-28
pubmed: 24980831
J Mol Biol. 1999 Oct 22;293(2):215-8
pubmed: 10529348
PLoS Biol. 2019 Oct 23;17(10):e3000397
pubmed: 31644535
PLoS Biol. 2019 Oct 25;17(10):e3000515
pubmed: 31652256
Cancer Genet Cytogenet. 2003 Mar;141(2):138-42
pubmed: 12606131
PLoS Comput Biol. 2015 Sep 11;11(9):e1004493
pubmed: 26360300
Cell. 2016 Mar 24;165(1):234-246
pubmed: 26924578
Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):146S-154S
pubmed: 9322882
J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30
pubmed: 18525458
Curr Biol. 1997 Jan 1;7(1):R44-6
pubmed: 9072170
J Clin Oncol. 2012 Nov 20;30(33):4148-54
pubmed: 23091096
Cancer Chemother Pharmacol. 2014 Apr;73(4):657-63
pubmed: 24469502
Pediatr Blood Cancer. 2006 Nov;47(6):795-800
pubmed: 16411206
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
Clin Cancer Res. 2012 Apr 1;18(7):1863-9
pubmed: 22344233
Sarcoma. 2011;2011:863210
pubmed: 21151650
Nat Commun. 2019 Jan 18;10(1):334
pubmed: 30659188
Sci Rep. 2017 Apr 27;7(1):1232
pubmed: 28450729
N Engl J Med. 2003 Feb 20;348(8):694-701
pubmed: 12594313
Trends Microbiol. 2015 Jul;23(7):401-7
pubmed: 25818802
Trends Pharmacol Sci. 2009 Oct;30(10):546-56
pubmed: 19762091
Drug Resist Updat. 2012 Feb-Apr;15(1-2):98-105
pubmed: 22483810
Cancer Genet Cytogenet. 2006 Apr 15;166(2):173-9
pubmed: 16631476
Molecules. 2018 Dec 04;23(12):
pubmed: 30518104
Clin Cancer Res. 2014 Sep 1;20(17):4584-97
pubmed: 24963049
Sci Transl Med. 2013 Sep 25;5(204):204ra132
pubmed: 24068739
Sci Transl Med. 2014 Nov 12;6(262):262ra156
pubmed: 25391482